Zealand Pharma CEO still has faith in obesity candidate from Boehringer Ingelheim collaboration
BI 456906, which could secure billion-kroner sums for Zealand Pharma, has major potential compared to other candidates, according to CEO Adam Steensberg. Analyst is more skeptical.
by christopher due karlsson, translated by christian radich hoffman
The high expectations remain intact for Zealand Pharma’s chief executive officer, Adam Steensberg, when it comes to the company’s obesity treatment candidate BI 456906 after German partner Boehringer Ingelheim published data from a phase II study last week.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
